Pilot Study Successfully Uses DNA Sequencing to Diagnose Brain Infections
Posted by: Candace Scott on: June 24, 2016 | Print This Page
In a proof-of-principle study, a team of physicians and bioinformatics experts at Johns Hopkins reports they were able to diagnose or rule out suspected brain infections using so-called next-generation genetic sequencing of brain tissue samples.
The team says its study, described online June 13 in Neurology: Neuroimmunology & Neuroinflammation, demonstrates that using computers to rapidly analyze huge amounts of genetic and biological information could be a cost-effective addition to a pathology lab’s toolkit. More than 50 percent of inflammatory disorders and infections of the brain go undiagnosed, which can lead to treatments for individual symptoms that can do more harm than good.
“By incorporating modern genetic sequencing techniques into pathology diagnostics, we were able to investigate the potential presence of infection in 10 subjects and found appropriate explanations of clinical problems in eight out of 10 patient cases examined in this study,” says Carlos Pardo-Villamizar, M.D., associate professor of neurology at the Johns Hopkins University School of Medicine. “We hope to develop this technique further as a way to bring the diagnosis rate of inflammatory brain disorders and infections closer to 100 percent so we can treat patients more effectively.”
In the study, the researchers first identified 10 people at The Johns Hopkins Hospital — six males and four females between the ages of 16 and 68 — with clinical signs of a brain infection, such as fever and rapid onset of neurological symptoms, like weakness in limbs, partial paralysis numbness, headache or seizures.
Each patient had a biopsy of a brain lesion — an area of inflamed, damaged tissue — first identified by MRI. Using commercially available genetic sequencing technologies that read millions of pieces of DNA at once, the researchers sequenced the DNA of the brain tissue for each person and compared the results to a database containing human and nonhuman DNA sequences, 2,817 bacterial genomes, 4,383 viral genomes and 26 single-cell pathogen genomes.
After subtracting out the human DNA results, they ranked the top three other species found in each sample that were thought to be potential infectious organisms.
In three patients, they said genetic sequencing definitively identified the cause of the infection as Mycobacterium tuberculosis, the bacterium that causes tuberculosis and sometimes infects the brain; JC virus, which is found in most people but is only typically infectious in people with weakened immune systems; or Epstein-Barr virus, a herpes virus most commonly known to cause mononucleosis in humans.
“Identifying organisms involved in brain infections is critical for establishing adequate treatments and, in the case of tuberculosis or viral infections, is a major challenge in clinical practice,” says Pardo-Villamizar.
The researchers report that genetic sequencing also revealed possible but unspecified infections in two other patients. In one patient, the researchers identified several bacteria species in the biopsy related to Delftia acidovorans, a rare, rod-shaped bacillus that physicians treated with antibiotics. In the other patient, they identified a relatively high number of sequences from Lactococcus, a normally noninfectious bacterium. However, they reanalyzed the sequence data a year later and found the sequences matched up to a newly emerging pathogen, Elizabethkingia — a genome that was unavailable during the original analysis. The bacterium, found in soil, has been linked mostly to newborn meningitis or inflammation of the membrane covering the brain.
“One of the limitations of using this kind of diagnostic tool is that we can only identify the pathogens for which we have the genetic sequences available,” says Steven Salzberg, Ph.D., a Bloomberg Distinguished Professor, a professor of biomedical engineering at Johns Hopkins and co-author of the study. “As we continue to sequence the genomes of more organisms, the tool will become steadily more powerful.” The cost for genetic sequencing using the latest technology is less than $500 per sample and takes a couple of days. The comparison of the DNA results to other species takes less than two hours.
In five patients, the research team says, the sequencing didn’t point to a specific pathogen as a cause. In those cases, negative findings helped clinicians to better understand the diseases those patients were experiencing. Pardo-Villamizar says a key value of the sequencing test is to avoid treating patients with drugs that may do harm. “If someone has an infection, then you don’t necessarily want to give them steroids to reduce inflammation. You’ll make the infection worse by knocking down the immune system,” says Pardo-Villamizar. “Having a correct diagnosis is the only way to ensure the best, individualized precision treatment.”
To bring this type of testing into widespread laboratory use, Pardo-Villamizar says more research is needed to establish a baseline of what organisms may be found in normal, healthy brains. They’ll also need a larger validation study of patients with an already established diagnosis to determine the rate of false positive or false negative results. The 2013 Global Burden of Disease Study estimates that 77,000 people die each year around the world due to brain inflammatory conditions. About 2,000 a year are due to active infections in the United States. Once the cause is determined, people can be treated with antivirals or antibiotics if an infection is suspected, or steroids if the cause is thought to be autoimmune.
Other authors of the study include Florian Breitwieser, Anupama Kumar, Haiping Hao, Peter Burger, Fausto Rodriguez, Michael Lim, Alfredo Quiñones-Hinojosa, Gary Gallia, Jeffrey Tornheim, Michael Melia and Cynthia Sears of the Johns Hopkins University School of Medicine.
Study funds were provided by grants from National Human Genome Research Institute (grant number R01 HG006677), the U.S. Army Research Office (grant number W911NF-14-1-0490) and the Bart McLean Fund for Neuroimmunology Research–Johns Hopkins Project Restore.
Vanessa McMains, 410-502-9410,firstname.lastname@example.org
Lauren Nelson, 410-955-8725, email@example.com